Management of sleep disorders in Parkinson's disease and multiple system atrophy

• Published in: Movement disorders 2017-05, Vol.32 (5), p.659-668
• Main Author: Videnovic, Aleksandar
• Format: Article
• Language: English
• Subjects: Atrophy; Chronobiology Disorders - complications; Chronobiology Disorders - physiopathology; Chronobiology Disorders - therapy; Disease Management; Disorders of Excessive Somnolence - complications; Disorders of Excessive Somnolence - physiopathology; Disorders of Excessive Somnolence - therapy; Humans; management; Movement disorders; multiple system atrophy; Multiple System Atrophy - complications; Multiple System Atrophy - therapy; Neurodegeneration; Neurodegenerative diseases; Parkinson Disease - complications; Parkinson Disease - therapy; Parkinson's; Parkinson's disease; REM Sleep Behavior Disorder - complications; REM Sleep Behavior Disorder - physiopathology; REM Sleep Behavior Disorder - therapy; Restless Legs Syndrome - complications; Restless Legs Syndrome - physiopathology; Restless Legs Syndrome - therapy; Side effects; Sleep; Sleep and wakefulness; Sleep Apnea Syndromes - complications; Sleep Apnea Syndromes - physiopathology; Sleep Apnea Syndromes - therapy; Sleep disorders; Sleep Initiation and Maintenance Disorders - complications; Sleep Initiation and Maintenance Disorders - physiopathology; Sleep Initiation and Maintenance Disorders - therapy; Sleep Wake Disorders - complications; Sleep Wake Disorders - physiopathology; Sleep Wake Disorders - therapy; Synuclein
• ISSN: 0885-3185; 1531-8257
• DOI: 10.1002/mds.26918

Parkinson's disease (PD) and multiple system atrophy (MSA) are disorders associated with α synuclein‐related neurodegeneration. Nonmotor symptoms are common hallmarks of these disorders, and disturbances of the sleep–wake cycle are among the most common nonmotor symptoms. It is only recently that sleep disturbances have received the attention of the medical and research community. Significant progress has been made in understanding the pathophysiology of sleep and wake disruption in alphasynucleinopathies during the past few decades. Despite these advancements, treatment options are limited and frequently associated with problematic side effects. Further studies that center on the development of novel treatment approaches are very much needed. In this article, the author discusses the current state of the management of disturbed sleep and alertness in PD and MSA. © 2017 International Parkinson and Movement Disorder Society